Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.07.08.194456: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Four randomized bases were included upstream of the barcodes on the IGHJ primer (gDNA libraries) and constant region primer (isotype libraries) for Illumina clustering. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources An enzyme-linked immunosorbent assay (ELISA) based on a protocol described in (Stadlbauer et al., 2020) was performed to detect anti-SARS-CoV and anti-SARS-CoV-2 spike RBD antibodies in plasma samples from COVID-19 patients. anti-SARS-CoVsuggested: Noneanti-SARS-CoV-2 spike RBDsuggested: NoneAfter … SciScore for 10.1101/2020.07.08.194456: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Four randomized bases were included upstream of the barcodes on the IGHJ primer (gDNA libraries) and constant region primer (isotype libraries) for Illumina clustering. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources An enzyme-linked immunosorbent assay (ELISA) based on a protocol described in (Stadlbauer et al., 2020) was performed to detect anti-SARS-CoV and anti-SARS-CoV-2 spike RBD antibodies in plasma samples from COVID-19 patients. anti-SARS-CoVsuggested: Noneanti-SARS-CoV-2 spike RBDsuggested: NoneAfter blocking plates with 3% non-fat milk in PBS containing 0.1% Tween 20, plasma samples were incubated at a dilution of 1:100 and bound antibodies were detected with goat anti-human IgM/HRP (Sigma: cat. anti-human IgM/HRPsuggested: NoneELISA testing of mAbs: ELISA conditions for mAbs were as described for COVID-19 plasma samples with the following modifications: two-fold serial dilutions of mAbs were tested, starting at 100 μg/mL for intra-COVID-19 convergent antibodies or peanut-specific negative mAb controls, or at 0.506 μg/mL for mAb CR3022; plates were coated overnight with RBD (0.1 μg per well), S1 (0.1 μg per well), or spike protein (0.3 μg per well); and bound mAbs were detected with rabbit anti-human IgG gamma chain-specific/HRP (Agilent: cat. anti-human IgG gamma chain-specific/HRPsuggested: NoneExperimental Models: Cell Lines Sentences Resources mAb expression and purification: Constructs were transiently transfected in HEK293-EBNA1-6E cells (NRC) at a density of 1.2-1.6 million cells/mL using 25 kDa linear polyethylenimine (PEI) at a 3:1 PEI:DNA ratio in OptiMEM reduced serum medium (Gibco), with a heavy chain: light chain ratio of 1:1. HEK293-EBNA1-6Esuggested: RRID:CVCL_HF20)Software and Algorithms Sentences Resources The V, D, and J gene segments and V-D (N1), and D-J (N2) junctions were identified using the IgBLAST alignment program (Ye et al., 2013). IgBLASTsuggested: (IgBLAST, RRID:SCR_002873)Analyses were conducted in R (Team, 2017) using base packages for statistical analysis and the ggplot2 package for graphics (Wickham, 2016). ggplot2suggested: (ggplot2, RRID:SCR_014601)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
